香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚賴該等內 容而引致的任何損失承擔任何責任。 Tycoon Group Holdings Limited 滿貫集團控股有限公司 （於開曼群島註冊成立的有限公司） （股份代號：3390） 截至2025年6月30日止六個月的中期業績公告 財務摘要 附註： EBITDA及經調整淨溢利各自為非香港財務報告準則計量。有關經調整淨溢利的定義、使用該等計量的理由及計 算詳情，請參閱本公告第25頁所載「EBITDA及經調整淨溢利（非香港財務報告準則計量）」一節。 1 • 本集團截至2025年6月30日止六個月（「回顧期內」或「2025年上半年」）的收入為510.1百萬港 元，較截至2024年6月30日止六個月（「去年同期」或「2024年上半年」）的435.0百萬港元增加 17.3%。 • 本集團2025年上半年的毛利為129.2百萬港元，較2024年上半年的107.8百萬港元增加19.8%。 • 毛利率由2024年上半年的24.8%增加0.5個百分點至2025年上 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚賴該等內 容而引致的任何損失承擔任何責任。 滿貫集團控股有限公司（「本公司」）董事會（「董事會」）謹此宣佈，本公司將於2025年8月29日（星期五） 舉行董事會會議，藉以（其中包括）考慮及通過本公司及其附屬公司截至2025年6月30日止六個月的中 期業績，及考慮派發中期股息（如有）。 代表董事會 滿貫集團控股有限公司 主席、執行董事兼行政總裁 王嘉俊 Tycoon Group Holdings Limited 滿貫集團控股有限公司 （於開曼群島註冊成立的有限公司） （股份代號：3390） 香港，2025年8月15日 董事會召開日期 於本公告日期，執行董事為王嘉俊先生；非執行董事為吳君豪先生、曹冉先生、梁艷女士、李家華 女士及劉家安先生；以及獨立非執行董事為鍾兆華先生、陳嘉麗女士及麥仲康先生。 ...

Group 1 - The core viewpoint of the article highlights significant adjustments in the overseas holdings of domestic private equity firms, particularly focusing on the changes in the portfolio of Jinglin Asset Management [1][2][3] Group 2 - Jinglin Asset's top holdings in US stocks as of the end of Q2 2025 include Meta, which accounts for 25.46% of its portfolio, with a market value exceeding $730 million [2] - The total value of Jinglin Asset's US stock holdings reached $2.873 billion, approximately 20.6 billion RMB, indicating a substantial shift towards internet companies [2] - The firm has sold off several major tech stocks, including Apple, UnitedHealth Group, Regeneron Pharmaceuticals, Pfizer, Legend Biotech, and ZTO Express [2] - The new focus on internet stocks is evident, with significant positions in companies like NetEase, Manbang Group, Pinduoduo, Futu Holdings, and 360 DigiTech [2] Group 3 - Jinglin Asset expressed optimism about China's future development, noting a shift in the competitive strength of Chinese companies from being undervalued to attracting global investment [3] - The new generation of Chinese entrepreneurs is seen as having advantages over the previous generation, leveraging a strong supply chain and engineering talent to create aesthetically pleasing products [3] - Dongfang Harbor's overseas fund has also accelerated its portfolio adjustments, reducing holdings in Nvidia, Amazon, and Apple, while increasing positions in Alphabet, Montreal Bank, and initiating purchases of Tesla, Netflix, and Coinbase [3]

Group 1 - The company, Man Kwan Group (03390), expects to report a loss of not less than HKD 7 million for the first half of 2024, compared to a profit of HKD 24.2 million for the same period in 2023 [1] - The challenges faced by the company's Chinese e-commerce division and a decrease in consumer purchasing sentiment are contributing factors to the expected loss [1] - Despite the anticipated loss, the company expects to achieve revenue growth and maintain stable gross margins in the first half of 2025 [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚賴該等內 容而引致的任何損失承擔任何責任。 Tycoon Group Holdings Limited 滿貫集團控股有限公司 （於開曼群島註冊成立的有限公司） （股份代號：3390） 盈利警告 本公告乃由滿貫集團控股有限公司（「本公司」，連同其附屬公司統稱「本集團」）根據香港聯合交易所 有限公司（「聯交所」）證券上市規則（「上市規則」）第13.09條及內幕消息條文（定義見上市規則）所作 出。 本公司董事（「董事」）會（「董事會」）謹此通知本公司股東（「股東」）及潛在投資者，根據本集團截至2025 年6月30日止六個月（「2025年上半年」）的未經審核綜合管理賬目的初步評估及目前可獲得的資料，相 比本集團截至2024年6月30日止六個月（「2024年上半年」）的除稅前溢利24.2百萬港元，預期本集團將 錄得虧損不少於7.0百萬港元。 本集團已於2025年上半年回購Combo Win Asia Limited（「CWA」，連同其附屬公司統稱為「CWA ...

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年7月31日 狀態: 新提交 公司名稱: 滿貫集團控股有限公司 (於開曼群島註冊成立的有限公司) 呈交日期: 2025年8月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 03390 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 10,000,000,000 | HKD | | 0.01 HKD | | 100,000,000 | | 增加 / 減少 (-) | | | | | | HKD | | | | 本月底結存 | | | 10,000,000,000 | HKD | | 0.01 HKD | | 100,000,000 | 本月底法定/註冊股本總額： HK ...

Group 1 - The company, Man Kwan Group, has entered into a subscription agreement with Jacobson Group Treasury Limited to issue 94 million shares at a subscription price of HKD 0.5 per share, which represents 11.75% of the company's existing share capital as of the announcement date [1][2] - The total proceeds from the subscription are expected to be HKD 47 million, with a net amount of approximately HKD 46.7 million after expenses, intended for investment in core business growth, supply chain and logistics improvement, and general working capital [1][2] - The board believes that the subscription will enhance the financial position of the group and provide operational funds for future developments and obligations, with the subscriber intending to hold the equity long-term [2] Group 2 - The collaboration with Jacobson Group, a leading pharmaceutical company, is expected to create strategic synergies, leveraging both parties' expertise in healthcare and health products [2] - The subscription agreement is considered to be on normal commercial terms and is deemed fair and reasonable, aligning with the overall interests of the company and its shareholders [2] - The partnership aims to capitalize on emerging market opportunities, optimize financial leverage, and ultimately enhance long-term shareholder value [2]

暴跌90%后再翻倍，此前"寂寂无名"的满贯集团(03390)过去一周吸引了众多市场资金的关注。 在上周三盘中一度经历了90%的股价暴跌后，周四满贯集团股价开盘即大幅上扬30%，至收盘时涨至 76.67%，盘中股价一度翻番，但距离两天前的3.1港元开盘价仍有很长的一段长征要走。 放在两天之前，作为公司的创始人、董事局主席和行政总裁，48岁的王嘉俊一定没有想到，其掌舵的满 贯集团会遭遇如此精准的狙击。 "这是很明显的一种常见做空手法，即瞄准高质押的企业标的，通过迅速抛售筹码，使标的公司股价急 速崩盘。"一位港股机构资深人士告诉智通财经APP，由于抛售速度极快，被质押方往往来不及补交保 证金或增加担保标的，导致质押股份被强制平仓，引发股价的加速度溃败。 4月16日晚间，满贯集团的公告亦证实了这一点。 公告称，公司主席兼控股股东王嘉俊最终控制的Tycoon Empire所持1.29亿股普通股，已于4月16日因股 价大幅下跌而遭到强制出售。董事会确认，集团业务经营保持正常及业务经营及财务状况并无重大变 动。 该机构资深人士坦言，依照公告，王嘉俊应该质押了公司至少16.12%的公司股票在第三方券商，这使 得满贯集团容易成 ...

Group 1 - The core viewpoint of the news is that Man Kwan Group (03390.HK) experienced extreme volatility in its stock price, with a significant drop of over 90% on April 16, followed by a recovery of over 130% on April 17, but the overall decline remains substantial [1] - The sharp decline on April 16 was attributed to forced selling of shares controlled by the company's chairman, Wang Jia Jun, due to the drastic drop in stock price [1] - Following the forced sale, Wang and Tycoon Empire retained 302 million shares, representing 37.75% of the company's total equity [1] Group 2 - Man Kwan Group is a comprehensive marketing management company in the health sector, providing one-stop services for brand agency, promotion, management, and distribution of health products across nearly 100,000 sales points in Hong Kong, Macau, and Southeast Asia [2] - In the annual report, the company reported a revenue of HKD 876 million for 2024, a year-on-year decrease of 26.9%, and a net profit attributable to shareholders of HKD 3.24 million, down 98.9% year-on-year [2] Group 3 - Investors raised concerns about the company's performance in 2024 following the stock price crash, with the company attributing the decline in performance to several factors, including the absence of one-time gains from the sale of CWA 51% equity in 2023, increased share-based payment expenses, and the negative impact of the equity sale on net profit [3]

Company Overview - Man Kwan Group (满贯集团) reported a significant stock price increase of 76.67%, closing at HKD 0.53 per share, with a trading volume of 363 million shares and a turnover of HKD 179 million, reflecting a volatility of 106.67% [1] - Despite the recent surge, the company has experienced a cumulative decline of 92.19% over the past month and 91.38% year-to-date, underperforming the Hang Seng Index by 4.97% [1] Financial Performance - For the fiscal year ending December 31, 2024, Man Kwan Group achieved total revenue of HKD 811 million, representing a year-on-year decrease of 26.91% [1] - The net profit attributable to shareholders was HKD 3 million, down 98.91% year-on-year, with a gross margin of 26.56% and a debt-to-asset ratio of 51.37% [1] Industry Valuation - Currently, there are no institutional investment ratings for Man Kwan Group [2] - The average price-to-earnings (P/E) ratio for the pharmaceutical and biotechnology industry is 5.89 times, with a median of 4.7 times. Man Kwan Group's P/E ratio stands at 74.07 times, ranking 73rd in the industry [2] - Comparatively, other companies in the sector have significantly lower P/E ratios, such as Excellence Pharmaceutical (0.63), King’s Ray Biotechnology (0.98), and others [2] Business Focus - Man Kwan Group is dedicated to providing high-quality traditional Chinese medicine, health supplements, skincare, personal care, and other health care products to residents in Hong Kong, Macau, and mainland China [2] - The company currently represents or distributes over 100 brands and is one of the top three distributors in the traditional Chinese medicine market [2] Major Shareholder Activity - On April 10, 2025, major shareholder Wang Jiajun increased his holdings by purchasing 38,000 shares at an average price of HKD 3.3 per share, bringing his total holdings to 431 million shares, which constitutes 53.88% of the company [3]